Melane Sampson, Author at BioTuesdays

Executive Moves

Dr. Torsten Malmström joins Spago as director CMC & supply

Spago Nanomedical (STO:SPAGO.ST; FRA:7UX.F) has announced that Torsten Malmström, PhD, has been appointed director of chemistry, manufacturing, and controls (CMC) and joins the company’s management team. Dr. Malmström...

March 11, 2026

Developments

bioAffinity initiates longitudinal study for CyPath Lung

bioAffinity Technologies (NASDAQ: BIAF; BIAFW) has initiated a planned large-scale, longitudinal clinical study for CyPath Lung, its noninvasive diagnostic test for the detection of early-stage lung cancer. The 2,000...

March 11, 2026

Developments

ACCP Journal publishes PK studies of Tonix’s TONMYA in fibromyalgia

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced that the American College of Clinical Pharmacology (ACCP) journal Clinical Pharmacology in Drug Development published results from clinical pharmacokinetic (PK) studies...

March 6, 2026

Developments

Volition announces first ever automated Nu.Q Vet Cancer Test

VolitionRx (NYSE American: VNRX) has announced the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test with closely held Fujifilm Vet Systems Co...

March 6, 2026

Developments

INOVIO and Akeso collaborate to advance GMB therapy

INOVIO (NASDAQ: INO) and Akeso (HKEX: 9926) have announced a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO’s DNA immunotherapy candidate, in combination with cadonilimab...

March 4, 2026

Executive Moves

Alterity names Dr. Daniel O. Claassen chief medical advisor

Alterity Therapeutics (ASX: ATH; NASDAQ: ATHE) has announced that Daniel O. Claassen, MD, PhD, has been appointed chief medical advisor. In addition to this role, Dr. Claassen will retain his academic appointment as...

March 4, 2026

Developments

Firefly nears launch of NVIDIA-powered human brain model

Firefly Neuroscience (NASDAQ: AIFF) has announced a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes. Through its acquisition of closely held Evoke...

March 4, 2026

Developments

FDA approves Perimeter’s Claire, first AI imaging device for breast cancer surgery

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that it has received FDA premarket approval (PMA) for Claire—formerly the Perimeter OCT B-Series with ImgAssist AI 2.0—the first AI-enabled imaging...

March 3, 2026

Developments

Rein doses first patient in Phase 2 trial of LTI-03 in IPF

Rein Therapeutics (NASDAQ: RNTX) has announced that the first patient has been dosed in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with...

March 3, 2026

Feature

Casp-Aid targeting neuronal neurodegeneration to restore cognition in Alzheimer disease

Closely held Casp-Aid is advancing a differentiated therapeutic strategy aimed at repairing damaged neurons responsible for cognitive impairment by targeting the root cause of neuronal damage in Alzheimer disease (AD)...

March 3, 2026

Author - Melane Sampson

Dr. Torsten Malmström joins Spago as director CMC & supply

bioAffinity initiates longitudinal study for CyPath Lung

ACCP Journal publishes PK studies of Tonix’s TONMYA in fibromyalgia

Volition announces first ever automated Nu.Q Vet Cancer Test

INOVIO and Akeso collaborate to advance GMB therapy

Alterity names Dr. Daniel O. Claassen chief medical advisor

Firefly nears launch of NVIDIA-powered human brain model

FDA approves Perimeter’s Claire, first AI imaging device for breast cancer surgery

Rein doses first patient in Phase 2 trial of LTI-03 in IPF

Casp-Aid targeting neuronal neurodegeneration to restore cognition in Alzheimer disease

Subscribe